ISRA vs ITEQ
VanEck Israel ETF against Amplify BlueStar Israel Technology ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
18%
10 shared positions
Fee gap
16 bp
ISRA is cheaper
1-year return gap
16.1 pts
ISRA is ahead
Larger fund
ISRA
$157M
Side by side
| ISRA | ITEQ | |
|---|---|---|
| Fund | VanEck Israel ETF | Amplify BlueStar Israel Technology ETF |
| Issuer | VanEck | Amplify |
| Category | Single Country | Single Country |
| Expense ratio | 0.59% | 0.75% |
| Assets | $157M | $109M |
| Average daily dollar volume | $239K | $122K |
| Listed | Jun 25, 2013 | Nov 2, 2015 |
| FrenzyCap score | 35 | 27 |
| 1-month return | +0.8% | +3.0% |
| 3-month return | +3.9% | −4.6% |
| Year to date | +12.8% | +6.9% |
| 1-year return | +20.8% | +4.7% |
| 30-day volatility | 15.1% | 18.7% |
| Worst drawdown, 1 year | −12.0% | −14.0% |
| Trailing 12-month yield | 1.31% | 0.79% |
| Holdings | 82 | 60 |
| Top 10 weight | 49.5% | 42.1% |
| Look-through P/E | — | — |
| Holdings vs fair value | +1.6% | — |
| Holdings above 200-day average | 71% | — |
| Net flow, latest 3 reported months | +$6.8M thru Jun 2026 | −$3.1M thru Jun 2026 |
| 30-day implied volatility | 30.2% | 33.3% |
| Holdings as of | as of Oct 8, 2026issuer data | as of Jun 30, 2026SEC filing |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
23% of ISRA · 25% of ITEQ
Sector mix of the stock holdings
| Sector | ISRA | ITEQ | Gap |
|---|---|---|---|
| Technology | 37.1% | 24.6% | +12.5% |
| Health Care | 9.2% | 1.0% | +8.2% |
| Industrials | 6.1% | 1.2% | +4.9% |
| Financials | 1.8% | 1.9% | −0.1% |
| Utilities | 0.9% | 1.8% | −1.0% |
| Materials | 0.7% | 0.0% | +0.7% |
More: full overlap table · ISRA holdings · ITEQ holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.